Different association of manganese superoxide dismutase gene polymorphisms with risk of prostate, esophageal, and lung cancers: Evidence from a meta-analysis of 20,025 subjects

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 3, 2013, Pages 1937-1943

  Sun, Guo Gui ^a   Wang, Ya Di ^b   Lu, Yi Fang ^c   Hu, Wan Ning ^a  

^a Department of Chemoradiotherapy   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Tangshan Worker's Hospital   (China)

Author keywords

Esophageal cancer; Lung cancer; Manganese superoxide dismutase; Polymorphism; Prostate cancer

Indexed keywords

EID: 84880423966     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.3.1937     Document Type: Article

References (48)

1. Ambrosone CB, Freudenheim JL, Thompson PA, et al (1999),Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breastcancer. Cancer Res, 59, 602-6
2. Arsova-Sarafinovska Z, Matevska N, Petrovski D, et al (2008). Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. Cell Biochem Funct, 26, 771-7.
3. Bica CG, de Moura da Silva LL, et al (2009). MnSOD gene polymorphism association with steroid-dependent cancer. Pathol Oncol Res, 15, 19-24.
4. Cai Q, Shu XO, Wen W, et al (2004). Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk, results from the Shanghai Breast Cancer Study. Breast Cancer Res. 6, 647-55.
5. Cheng YJ, Wang YD, Liu Q, et al (2009). Occurrence and development relation between superoxide dismutase gene polymorphism and esophagus. Chin J Oncol, 31, 831-5.
6. Choi JY, Neuhouser ML, Barnett M, et al (2007). polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev, 16, 1115-20.
7. Choi JY, Neuhouser ML, Barnett MJ, et al (2008). Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis, 29, 964-70.
8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
9. di Martino E, Hardie LJ, Wild CP, et al (2007). The NAD(P)H, quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med, 9, 341-7.
10. Egan KM, Thompson PA, Titus-Ernstoff L, Moore JH, Ambrosone CB (2003). MnSOD polymorphism and breast cancer in a population-based case-control study. Cancer Lett, 199, 27-33.
11. Ergen HA, Narter F, Timirci O, Isbir T (2007). Effects of manganese superoxide dismutase Val-9Ala polymorphism on prostate cancer. Anticancer Res, 27, 1227-30.
12. Ho JC, Mak JC, Ho SP, et al (2006). Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong. J Thorac Oncol, 1, 648-53.
13. Hung RJ, Boffetta P, Brennan P, et al (2004). Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis, 25, 973-8.
14. Iguchi T, Sugita S, Wang CY, et al (2009). MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo, 23, 7-12.
15. Iguchi T, Wang CY, Delongchamps NB, et al (2008). Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology, 72, 238-41.
16. Kang D, Lee KM, Park SK, et al (2007). Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev, 16, 1581-6.
17. Komatsu M, Kuroda M, Wang Y, et al (2005). Manganese superoxide dismutase overexpression changes plating efficiency bidirectionally according to change in redox for SaOS2 human osteosarcoma cell line. Int J Oncology, 26, 853-62.
18. Li H, Kantoff PW, Giovannucci E, et al (2005). Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res, 65, 2498-504.
19. Li N, Oberley TD, Oberley LW, Zhong W (1998). Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate, 35, 221-33.
20. Lin P, Hsueh YM, Ko JL, et al (2003). Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer, 40, 123-9.
21. Liu G, Zhou W, Park S, et al (2004). The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms. Cancer, 101, 2802-8.
22. Mantel-Haenszel, Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
23. Mikhak B, Hunter DJ, Spiegelman D, et al (2008). Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis, 29, 2335-40.
24. Mitrunen K, Sillanpaa V, Kataja M, et al (2001). Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis, 22, 827-9.
25. Murphy SJ, Hughes AE, Patterson CC, et al (2007). A populationbased association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis, 28, 1323-28.
26. Oberley TD (2004). Mitochondria, manganese superoxide dismutase, and cancer. Antioxid Redox Signal, 6, 483-7.
27. Orrenius S, Gogvadze V, Zhivotovsky B (2007). Mitochondrial oxidative stress, implications for cell death. Annu Rev Pharmacol Toxicol, 47, 143-83.
28. Soini Y, Vakkala M, Kahlos K Pääkkö P, Kinnula V (2001). MnSOD expression is less frequent in tumour cells of invasive breast carcinomas than in situ carcinomas or nonneoplastic breast epithelial cells. J Pathol, 195, 156-62.
29. Sun GG,Hu WN,Wang YD,Yang CR,Lu YF (2012). Bidirectional regulation of manganese superoxide dismutase (MnSOD) on the radiosensitivity of esophageal cancer cells. Asian Pac J Cancer Prev, 13, 1-9.
30. Sun L, König IR, Homann N (2009). Manganese superoxide dismutase (MnSOD) polymorphism, alcohol, cigarette smoking and risk of oesophageal cancer. Alcohol Alcohol, 44, 353-7.
31. Sutton A, Khoury H, Prip-Buus C, et al (2003). The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics, 13, 145-57.
32. Swerissen H, Belfrage J, Weeks A, et al (2006). A randomised control trial of a self-management program for people with a chronic illness from Vientnamese, Chinese, Italian and Greek backgrounds. Patient Educ Couns, 64, 360-8.
33. Taufer M, Peres A, de Andrade VM, et al (2005). Is the Val16Ala manganese superoxide dismutase polymorphism associated with the aging process? J Gerontol A Biol Sci Med Sci, 60, 432-438.
34. Tong SY, Lee JM, Song ES, et al (2009) Functional polymorphism in manganese superoxide dismutase and antioxidant status, their interactions on the risk of cervical intraepithelial neoplasia and cervical cancer. Gynecol Oncol, 115, 272-6.
35. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2009). Redox regulation of cell Survival. Antioxid Redox Signal, 10, 1343-74.
36. Wang LI, Miller DP, Sai Y, et al (2001). Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst, 93, 1818-21.
37. Wang LI, Neuberg D, Christiani DC (2004). Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. J Occup Environ Med, 46, 556-64.
38. Wang MC, Guo MF, Zhao GQ (2006). Research on mRNA expression level of MnSOD gene in prostate cancer and benign prostatic hyperplasia tissue. Chin J Gerontol, 26, 164-5.
39. Wang S, Wang F, Shi X, et al (2009). Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk-A meta-analysis. Eur J Cancer, 45, 2874-81.
40. Wang Y, Kuroda M, Gao XS, et al (2005). Hydrogen peroxide overload increases adriamycin-induced apoptosis of SaOS2FM, a manganese superoxide dismutaseoverexpressing human osteosarcoma cell line. Int J Oncol, 26, 1291-300.
41. Woodson K, Tangrea JA, Lehman TA, et al (2001). Manganese superoxide dismutase (MnSOD) polymorphism, alphatocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control, 14, 513-8.
42. Yan T, Oberley LW, Zhong W, St Clair DK (1996). Manganesecontaining superoxide dismutase overexpression causes phenotypic reversion in SV-40 transformed human lung fibroblasts. Cancer Res, 56, 2864-71.
43. Zejnilovic J, Akev N, Yilmaz H, Isbir T (2009). Association between manganese superoxide dismutase polymorphism and risk of lung cancer. Cancer Genet Cytogenet, 189, 1-4
44. Zhang HJ, Yan T, Oberley TD, Oberley LW (1999) Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype. Cancer Res, 59, 6276-83,.
45. Zhao Y, Xuo Y, Oberley LW (2001). Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis mode. Cancer Res, 61, 6082-8.
46. Zhong W, Oberley LW, Oberley TD, St Clair DK (1997). Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene, 14, 481-90.
47. Zhong W, Oberley LW(2005). Suppression of malignant phenotype of human glioma cells by overexpression of Manganese superoxide dismutase. Oncogene, 14, 481-90.
48. Zwacka RM, Duds L, Epperly MW, et al (1993). Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Nate Acad Sci USA, 90, 3113- 7.